Publications by authors named "A S Estrin"
Despite current treatments, patients with myasthenia gravis (MG) experience unpredictable and inadequately controlled symptoms, lending to variability in the clinical and economic burden of disease. However, limited data are available on MG healthcare costs, and specifically, no data on patients initiating second-line therapy. Using claims data from the IBM® MarketScan® database, we assessed patient characteristics, healthcare resource utilization, and costs among MG patients initiating second-line therapy, and identified potential factors associated with high healthcare costs over a two-year follow-up period.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to evaluate the real-world use of emicizumab in adult patients with hemophilia A without inhibitors, focusing on healthcare utilization and costs associated with treatment.
- - Data from 71 patients showed that after starting emicizumab, healthcare costs and utilization increased initially during the induction period compared to the maintenance period, with hemophilia treatment costs comprising over 95% of total healthcare expenses.
- - The findings suggest that while emicizumab is effective for treating hemophilia A, the associated healthcare costs are substantial, highlighting the need for careful financial management in patient care.
A recessed vulva is a conformational abnormality that predisposes affected dogs to urinary tract infections. An episioplasty can be recommended for correction of this abnormality when medical management of recurrent urinary tract infection fails. The objective of this study was to investigate the type and incidence of urogenital abnormalities visualized by cystoscopy in dogs presenting for episioplasty.
View Article and Find Full Text PDFReal-world data (RWD) reflecting patient treatment in routine clinical practice can be used to develop external control groups for single-arm trials. External controls can provide valuable benchmark results on potential comparator drug effectiveness, particularly in rare indications when randomized controlled trials are either infeasible or unethical. This paper describes lessons learned from a descriptive real-world external control cohort study conducted to provide benchmark data for a single-arm clinical trial in a rare oncology biomarker driven disease.
View Article and Find Full Text PDFObjective: To describe the causes of intraoperative delays and the changes in delays and surgical workflow with the level of training of the primary surgeon.
Study Design: Prospective observational study.
Sample Population: Seventy-three small animal surgical procedures performed at an academic teaching institution between January 17, 2018 and April 10, 2018.